Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 15/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20579724 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL29784689 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL4351105 | 0.88 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL1321676 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL7617534 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL290702 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL29374837 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL6761745 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL31462888 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20769890 | 0.83 | SLC29A1 (0.71) | SLC29A1CYP3A4LMNARAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461039-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CILOSTAZOL AND AN ADENOSINE UPTAKE INHIBITOR | OTSUKA PHARMA CO LTD (JP) | 2014-10-22 | — | — | EP | claimed |
| US-20050165030-A1 | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-28 | — | — | US | claimed |
| EP-1461039-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MULTIFUNCTIONAL PHOSPHODIESTERASE INHIBITOR AND AN ADENOSINE UPTAKE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-29 | — | — | EP | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| WO-2003057222-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A MULTIFUNCTIONAL PHOSPHODIESTERASE INHIBITOR AND AN ADENOSINE UPTAKE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-5780450-A | ADMINISTERING TOPICALLY, PARENTERALLY, ORALLY | ALCON LABORATORIES, INC. (US) | 1998-07-14 | — | — | US | claimed |
| WO-1997018815-A2 | THE USE OF ADENOSINE UPTAKE INHIBITORS FOR TREATING RETINAL OR OPTIC NERVE HEAD DAMAGE | ALCON LABORATORIES, INC. (US) | 1997-05-29 | — | — | WO | claimed |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| EP-4072671-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-05-06 | — | — | US | disclosed |
| US-5780450-A | ADMINISTERING TOPICALLY, PARENTERALLY, ORALLY | ALCON LABORATORIES, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0814810-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997018815-A2 | THE USE OF ADENOSINE UPTAKE INHIBITORS FOR TREATING RETINAL OR OPTIC NERVE HEAD DAMAGE | ALCON LABORATORIES, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5629298-A | INCREASING CONTRACTILE PERFORMANCE, ADENOSINE TRANSPORT INHIBITORS USED AS POTENTIATORS | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1997-05-13 | — | — | US | disclosed |
| WO-1996028163-A1 | ADENOSINE AS A POSITIVE INOTROP IN THE COMPROMISED HEART | UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1991010907-A1 | PHARMACOLOGICALLY ACTIVE COMPOUND SCREENING ANTIBODIES AND HIERARCHICAL CLUSTER ANALYSIS | SYNBIOTICS CORPORATION (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | SLC29A1 2159/4885CYP3A4 4876/4885LMNA 1462/4885 |
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINH1 | SLC29A1 686/4885CYP3A4 1462/4885LMNA 675/4885 |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINE1 | SLC29A1 343/4885CYP3A4 1031/4885LMNA 1612/4885 |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | SERPINA2, SERPINB1, SERPINE1 | SLC29A1 898/4885CYP3A4 1868/4885LMNA 1462/4885 |
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | SERPINA2, SERPINC1, SERPINB1 | SLC29A1 494/4885CYP3A4 1236/4885LMNA 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.